Page 36 - Read Online

89. Christensen LH, Breiting VB, Aasted A, Jørgensen A, Kebuladze I. Long-term a permanent 2.5% polyacrylamide hydrogel softtissue filler. Dermatol Surg
effects of polyacrylamide hydrogel on human breast tissue. Plast Reconstr 2010;36 Suppl 3:1819-29.
Surg 2003;111:1883-90. 99. Fernández-Cossío S, Castaño-Oreja MT. Biocompatibility of two novel
90. Breiting V, Aasted A, Jørgensen A, Opitz P, Rosetzsky A. A study on patients dermal fillers: histological evaluation of implants of a hyaluronic acid filler
treated with polyacrylamide hydrogel injection for facial corrections. and a polyacrylamide filler. Plast Reconstr Surg 2006;117:1789-96.
Aesthetic Plast Surg 2004;28:45-53. 100. Christensen L, Breiting V, Bjarnsholt T, Eickhardt S, Høgdall E, Janssen M,
91. Von Buelow S, Von Heimburg D, Pallua N. Efficacy and safety of Pallua N, Zaat SA. Bacterial infection as a likely cause of adverse reactions
polyacrylamide hydrogel for facial soft-tissue augmentation. Plast Reconstr to polyacrylamide hydrogel fillers in cosmetic surgery. Clin Infect Dis
Surg 2005;116:1137-46. 2013;56:1438-44.
92. Von Buelow S, Pallua N. Efficacy and safety of polyacrylamide hydrogel
for facial soft-tissue augmentation in a 2-year follow-up: a prospective 101. Nygart JF, Nygart VA, Borggren M, Tvede M. Effect of prophylactic antibiotics
multicenter study for evaluation of safety and aesthetic results in 101 on polyacrylamide gel safety in facial augmentation. J Drugs Dermatol
patients. Plast Reconstr Surg 2006;118:S85-91. 2014;13:571-3.
93. De Santis G, Jacob V, Baccarani A, Pedone A, Pinelli M, Spaggiari A, 102. Ersek RA, Beisang AA 3rd. Bioplastique: a new texture copolymer
Guaraldi G. Polyacrylamide hydrogel injection in the management of microparticle promises permanence in soft tissue augmentation. Plast
human immunodeficiency virus-related facial lipoatrophy: a 2-year clinical Reconstr Surg 1991;33:693-702.
experience. Plast Reconstr Surg 2008;121:644-53. 103. Rudolph CM, Soyer HP, Schuller-Petrovic S, Kerl H. Bioplastiquegranulom.
94. Negredo E, Puig J, Aldea D, Medina M, Estany C, Pérez-Alvarez N, Rodríguez- Hautarzt 1997;48:749-52.
Fumaz C, Muñoz-Moreno JA, Higueras C, Gonzalez-Mestre V, Clotet B. Four- 104. Hoffmann C, Schuller-Petrovic S, Soyer HP, Kerl H. Adverse reactions after
year safety with polyacrylamide hydrogel to correct antiretroviral-related cosmetic augmentation with permanent biologically inert implant materials.
facial lipoatrophy. AIDS Res Hum Retroviruses 2009;25:451-5. J Am Acad Dermatol 1999;40:100-2.
95. Wolters M, Lampe H. Prospective multicenter study for evaluation of safety, 105. Rudolph CM, Soyer HP, Schuller-Petrovic S, Kerl H. Foreign body granulomas
efficacy, and esthetic results of crosslinked polyacrylamide hydrogel in 81 due to injectable aesthetic microimplants. Am J Surg Pathol 1999;23:113-7.
patients. Dermatol Surg 2009;35 Suppl 1:338-43. 106. Margolis DM. Treatment for lipoatrophy: facing the real costs. AIDS
96. Mole B, Gillaizeau F, Carbonnel E, Pierre I, Brazille P, Grataloup C, Mercier S, 2007;21:1819-20.
Duracinsky M, Weiss L, Piketty C. Polyacrylamide hydrogel injection in the 107. Nelson L, Stewart KJ. Experience in the treatment of HIV-associated
management of human immunodeficiency virus-related facial lipoatrophy: lipodystrophy. J Plast Reconstr Aesthet Surg 2008;61:366-71.
results of the LIPOPHILL open-label study. AIDS Res Hum Retroviruses 108. Karim RB, De Lint CA, Van Galen SR, Van Rozelaar L, Nieuwkerk PT,
2012;28:251-8.
97. Lafaurie M, Dolivo M, Girard PM, May T, Bouchaud O, Carbonnel E, Madelaine Askarizadeh E, Hage JJ. Long-term effect of polyalkylimide gel injections
I, Loze B, Porcher R, Molina JM; ANRS 132 SMILE study group. Polylactic on severity of facial lipoatrophy and quality of life of HIV-positive patients.
acid vs. polyacrylamide hydrogel for treatment of facial lipoatrophy: a Aesthetic Plast Surg 2008;32:873-8.
randomized controlled trial [Agence Nationale de Recherches sur le SIDA 109. Mallewa JE, Wilkins E, Vilar J, Mallewa M, Doran D, Back D, Pirmohamed
et les Hépatites Virales (ANRS) 132 SMILE]. HIV Med 2013;14:410-20. M. HIV-associated lipodystrophy: a review of underlying mechanisms and
98. Narins RS, Coleman WP 3rd, Rohrich R, Monheit G, Glogau R, Brandt F, therapeutic options. J Antimicrob Chemother 2008;62:648-60.
Bruce S, Colen L, Dayan S, Jackson I, Maas C, Rivkin A, Sclafani A, Spivak JC. 110. Hönig J. Cheek augmentation with Bio-Alcamid in facial lipoatrophy in HIV
12-Month controlled study in the United States of the safety and efficacy of seropositive patients. J Craniofac Surg 2008;19:1085-8.

Plast Aesthet Res || Vol 3 || Mar 23, 2016 99